The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
 
Andrea Necchi
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Pierre Fabre; Seagen
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Celgene; Merck Sharp & Dohme; Roche
 
Domenico Magazzu
No Relationships to Disclose
 
Andrea Anichini
No Relationships to Disclose
 
Daniele Raggi
No Relationships to Disclose
 
Patrizia Giannatempo
No Relationships to Disclose
 
Nicola Nicolai
No Relationships to Disclose
 
Maurizio Colecchia
No Relationships to Disclose
 
Biagio Paolini
No Relationships to Disclose
 
Elisa Coradeschi
No Relationships to Disclose
 
Elena Tassi
No Relationships to Disclose
 
Giulia Grazia
No Relationships to Disclose
 
Roberta Mortarini
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Elena Togliardi
No Relationships to Disclose
 
Flavio Crippa
No Relationships to Disclose
 
Roberto Salvioni
No Relationships to Disclose
 
Alessandro M. Gianni
No Relationships to Disclose
 
Pinuccia Valagussa
No Relationships to Disclose